Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

Arthur R, Wang Y, Ye K, Glass AG, Ginsberg M, Loudig O, Rohan T.

Breast Cancer Res Treat. 2018 Jul;170(1):203. doi: 10.1007/s10549-018-4780-4.

PMID:
29644560
2.

MicroRNA expression in benign breast tissue and risk of subsequent invasive breast cancer.

Rohan T, Ye K, Wang Y, Glass AG, Ginsberg M, Loudig O.

PLoS One. 2018 Feb 12;13(2):e0191814. doi: 10.1371/journal.pone.0191814. eCollection 2018.

3.

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choeurng V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL.

J Clin Oncol. 2018 Feb 20;36(6):581-590. doi: 10.1200/JCO.2017.74.2940. Epub 2017 Nov 29.

4.

Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

Arthur R, Wang Y, Ye K, Glass AG, Ginsberg M, Loudig O, Rohan T.

Breast Cancer Res Treat. 2017 Oct;165(3):623-631. doi: 10.1007/s10549-017-4347-9. Epub 2017 Jun 22. Erratum in: Breast Cancer Res Treat. 2018 Apr 11;:.

5.

Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.

Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LLC, du Plessis M, Choeurng V, Haddad Z, Buerki C, Davicioni E, Weinmann S, Freedland SJ, Klein EA, Karnes RJ, Feng FY.

J Clin Oncol. 2017 Jun 20;35(18):1991-1998. doi: 10.1200/JCO.2016.70.2811. Epub 2017 Mar 30. Review.

6.

Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

Gierach GL, Curtis RE, Pfeiffer RM, Mullooly M, Ntowe EA, Hoover RN, Nyante SJ, Feigelson HS, Glass AG, Berrington de Gonzalez A.

JAMA Oncol. 2017 Feb 9;3(2):186-193. doi: 10.1001/jamaoncol.2016.3340. Epub 2016 Oct 6.

7.

Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting.

Glass AG, Leo MC, Haddad Z, Yousefi K, du Plessis M, Chen C, Choeurng V, Abdollah F, Robbins B, Ra S, Richert-Boe KE, Buerki C, Pearson K, Davicioni E, Weinmann S.

J Urol. 2016 Jun;195(6):1748-53. doi: 10.1016/j.juro.2015.11.044. Epub 2015 Nov 26.

PMID:
26626216
8.

Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH, Robinson BD, Ginsberg M, Gertler FB, Glass AG, Sparano JA, Condeelis JS, Jones JG.

J Natl Cancer Inst. 2014 Jun 3;106(8). pii: dju136. doi: 10.1093/jnci/dju136. Print 2014 Aug.

9.

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.

Weycker D, Barron R, Edelsberg J, Kartashov A, Legg J, Glass AG.

BMC Health Serv Res. 2014 Apr 27;14:189. doi: 10.1186/1472-6963-14-189.

10.

Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.

Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J.

Support Care Cancer. 2014 May;22(5):1363-73. doi: 10.1007/s00520-013-2094-y. Epub 2014 Jan 4.

PMID:
24389827
11.

Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.

Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, Richhariya A, Dodge T, Wolff GG, Balakumaran A, Edelsberg J.

Support Care Cancer. 2013 Dec;21(12):3279-86. doi: 10.1007/s00520-013-1887-3. Epub 2013 Jul 25.

PMID:
23884473
12.

Efficacy of screening in preventing cervical cancer among older women.

Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS.

Cancer Causes Control. 2013 Sep;24(9):1653-60. doi: 10.1007/s10552-013-0239-4. Epub 2013 Jun 7.

PMID:
23744043
13.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.

14.

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C, Oeggerli M, Germann M, Gluderer S, Stocker H, Andreozzi M, Thalmann GN, Cecchini MG, Zellweger T, Stürm S, Koivisto PA, Helin HJ, Gelmann EP, Glass AG, Gasser TC, Terracciano LM, Bachmann A, Wyler S, Bubendorf L, Rentsch CA.

Prostate. 2012 Nov;72(15):1678-87. doi: 10.1002/pros.22521. Epub 2012 Apr 2.

PMID:
22473923
15.

Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.

Lacey JV Jr, Chia VM, Rush BB, Carreon DJ, Richesson DA, Ioffe OB, Ronnett BM, Chatterjee N, Langholz B, Sherman ME, Glass AG.

Int J Cancer. 2012 Oct 15;131(8):1921-9. doi: 10.1002/ijc.27457. Epub 2012 Mar 14.

16.

A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk.

Kabat GC, Kandel RA, Glass AG, Jones JG, Olson N, Duggan C, Ginsberg M, Negassa A, Rohan TE.

J Oncol. 2011;2011:970804. doi: 10.1155/2011/970804. Epub 2011 Aug 22.

17.

A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.

Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409. doi: 10.1158/1055-9965.EPI-11-0206. Epub 2011 May 20. Erratum in: Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1390-1.

18.

A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer.

Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE.

Cancer Causes Control. 2010 Jun;21(6):821-8. doi: 10.1007/s10552-010-9508-7. Epub 2010 Jan 19.

19.

Risk factors for breast cancer in women biopsied for benign breast disease: a nested case-control study.

Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, Ginsberg M, Kandel RA, Glass AG, Rohan TE.

Cancer Epidemiol. 2010 Feb;34(1):34-9. doi: 10.1016/j.canep.2009.12.005. Epub 2010 Jan 15.

20.

Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia.

Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B.

J Clin Oncol. 2010 Feb 10;28(5):788-92. doi: 10.1200/JCO.2009.24.1315. Epub 2010 Jan 11.

21.

Age-appropriate use of human papillomavirus vaccines in the U.S.

Castle PE, Fetterman B, Akhtar I, Husain M, Gold MA, Guido R, Glass AG, Kinney W.

Gynecol Oncol. 2009 Aug;114(2):365-9. doi: 10.1016/j.ygyno.2009.04.035. Epub 2009 May 22. Review.

22.

Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies.

Lacey JV Jr, Mutter GL, Nucci MR, Ronnett BM, Ioffe OB, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME.

Cancer. 2008 Oct 15;113(8):2073-81. doi: 10.1002/cncr.23808.

23.

PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma.

Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME.

Cancer Res. 2008 Jul 15;68(14):6014-20. doi: 10.1158/0008-5472.CAN-08-1154.

24.

Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification.

Sherman ME, Ronnett BM, Ioffe OB, Richesson DA, Rush BB, Glass AG, Chatterjee N, Duggan MA, Lacey JV Jr.

Int J Gynecol Pathol. 2008 Jul;27(3):318-25. doi: 10.1097/PGP.0b013e3181659167.

PMID:
18580308
25.

Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells.

Kaulfuss S, Grzmil M, Hemmerlein B, Thelen P, Schweyer S, Neesen J, Bubendorf L, Glass AG, Jarry H, Auber B, Burfeind P.

Mol Endocrinol. 2008 Jul;22(7):1606-21. doi: 10.1210/me.2006-0546. Epub 2008 May 1.

26.

Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan.

Lacey JV Jr, Ioffe OB, Ronnett BM, Rush BB, Richesson DA, Chatterjee N, Langholz B, Glass AG, Sherman ME.

Br J Cancer. 2008 Jan 15;98(1):45-53. Epub 2007 Nov 20.

27.

Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions.

Gravitt PE, van Doorn LJ, Quint W, Schiffman M, Hildesheim A, Glass AG, Rush BB, Hellman J, Sherman ME, Burk RD, Wang SS.

J Clin Microbiol. 2007 Oct;45(10):3245-50. Epub 2007 Aug 15.

28.

Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer.

Cui Y, Vogt S, Olson N, Glass AG, Rohan TE.

Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1682-5. Erratum in: Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2173.

29.

Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Glass AG, Lacey JV Jr, Carreon JD, Hoover RN.

J Natl Cancer Inst. 2007 Aug 1;99(15):1152-61. Epub 2007 Jul 24.

PMID:
17652280
30.

Abnormal outcomes following cervical cancer screening: event duration and health utility loss.

Insinga RP, Glass AG, Myers ER, Rush BB.

Med Decis Making. 2007 Jul-Aug;27(4):414-22. Epub 2007 Jun 21.

PMID:
17585005
31.

Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study.

Pratt MM, Sirajuddin P, Poirier MC, Schiffman M, Glass AG, Scott DR, Rush BB, Olivero OA, Castle PE.

Mutat Res. 2007 Nov 1;624(1-2):114-23. Epub 2007 May 5.

32.

Human papillomavirus prevalence in women who have and have not undergone hysterectomies.

Castle PE, Schiffman M, Glass AG, Rush BB, Scott DR, Wacholder S, Dunn A, Burk RD.

J Infect Dis. 2006 Dec 15;194(12):1702-5. Epub 2006 Nov 3.

PMID:
17109342
33.

Cervical HPV DNA detection as a predictor of a recurrent SIL diagnosis among untreated women.

Castle PE, Zemlo TR, Burk RD, Scott DR, Sherman ME, Lorincz AT, Kurman RJ, Glass AG, Rush BB, Liaw KL, Schiffman M.

J Low Genit Tract Dis. 2001 Jul;5(3):138-43.

PMID:
17050958
34.

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG.

Ann Pharmacother. 2006 Mar;40(3):402-7. Epub 2006 Feb 21.

PMID:
16492793
35.

Response to "Use of cervical cancer screening among insured women: the extent of missed opportunities" [Health Policy 73 (2005) 194-201].

Insinga RP, Glass AG, Rush BB.

Health Policy. 2006 Aug;77(3):245-6. Epub 2005 Nov 16. No abstract available.

PMID:
16297495
36.

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M.

J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9.

PMID:
16030305
37.

Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer.

Castle PE, Schiffman M, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Wacholder S, Lorincz AT.

Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1311-4.

38.

The health care costs of cervical human papillomavirus--related disease.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):114-20.

PMID:
15295351
39.

Diagnoses and outcomes in cervical cancer screening: a population-based study.

Insinga RP, Glass AG, Rush BB.

Am J Obstet Gynecol. 2004 Jul;191(1):105-13.

PMID:
15295350
40.

Prostate cancer screening and mortality: a case-control study (United States).

Weinmann S, Richert-Boe K, Glass AG, Weiss NS.

Cancer Causes Control. 2004 Mar;15(2):133-8.

PMID:
15017125
41.

Pap screening in a U.S. health plan.

Insinga RP, Glass AG, Rush BB.

Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):355-60.

42.

Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer.

Castle PE, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Wacholder S, Burk RD, Manos MM, Schussler JE, Macomber P, Schiffman M.

J Clin Microbiol. 2003 Sep;41(9):4022-30.

43.

Comparison of documented and recalled histories of exposure to diagnostic x-rays in case-control studies of thyroid cancer.

Berrington de Gonzalez A, Ekbom A, Glass AG, Galanti MR, Grimelius L, Allison MJ, Inskip PD.

Am J Epidemiol. 2003 Apr 1;157(7):652-63.

PMID:
12672685
44.

Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer.

Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Mihatsch MJ, Gelmann EP, Bubendorf L.

Prostate. 2003 Apr 1;55(1):20-9.

PMID:
12640657
45.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
46.

Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.

Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F, Schiffman M.

Cancer. 2002 Nov 15;95(10):2145-51.

47.

A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women.

Castle PE, Wacholder S, Lorincz AT, Scott DR, Sherman ME, Glass AG, Rush BB, Schussler JE, Schiffman M.

J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14.

PMID:
12237286
48.

Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies.

Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M.

J Infect Dis. 2002 Sep 1;186(5):598-605. Epub 2002 Jul 29.

PMID:
12195346
49.

Viral load of human papillomavirus and risk of CIN3 or cervical cancer.

Lorincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S, Rush BB, Gravitt PE, Schussler JE, Schiffman M.

Lancet. 2002 Jul 20;360(9328):228-9.

PMID:
12133661
50.

Human leukocyte antigen class I alleles and cervical neoplasia: no heterozygote advantage.

Wang SS, Hildesheim A, Gao X, Schiffman M, Herrero R, Bratti MC, Sherman ME, Barnes WA, Greenberg MD, McGowan L, Mortel R, Schwartz PE, Zaino RJ, Glass AG, Burk RD, Karacki P, Carrington M.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):419-20. No abstract available.

Supplemental Content

Loading ...
Support Center